ABAlisdair M. Boag

Alisdair M. Boag

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alisdair M. Boag has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical significance of identification of Sphingomonas paucimobilis on bacterial culture in companion dogs and cats.

    by Perrine Henry, Devon Russell, Gavin Paterson, Silke Salavati, Alisdair Boag

    Background : Sphingomonas paucimobilis is part of the commensal microbiota of many animals but considered an emerging opportunistic pathogen in humans. Its occurrence and clinical relevance in dogs and cats is unknown. Objectives : We aimed to investigate the clinical significance of identification of S. paucimobilis on bacterial culture samples from dogs and cats. Methods : Retrospective longitudinal study. Medical records of dogs and cats with documented growth of S. paucimobilis from a single veterinary hospital were reviewed. Characteristics of the isolate (site, quantitative assessment, co-infections, sensitivity testing) and potential inciting causes (concurrent antibiotic treatment, immunosuppression, comorbidities) were retrieved. When possible, follow-up data were collected to document response to treatment and outcomes. Results : Ninety microbiology reports from 80 dogs and 10 cats were included. The most common site of isolation was the respiratory tract (33/90) followed by urine and skin (13/90 each). Pure growths were less common (9/90) than mixed. Sensitivity testing was only available from three cases. Most animals were treated with antimicrobials (70/90). Response to treatment was available for 78 animals and outcomes for 87. Most animals experienced a resolution of clinical signs (66/78), of which 12/66 had negative repeat culture. Thirty-four animals died during the follow-up period; five of those (all isolated from the respiratory tract of dogs, one of which a pure growth) were possibly related to S. paucimobilis infection. Conclusion : S. paucimobilis isolated from dogs and cats is often incidental, however it may be clinically significant when isolated from the respiratory tract in dogs.


  • Open Access

    A Multicenter, Retrospective Analysis of Long-Term Survival in 255 Dogs With Pheochromocytoma Treated With Alpha-Adrenoreceptor Antagonists or Surgery (2010–2021)

    by Matthew M. E. Steele, Marit F. van Den Berg, Sara Galac, Ana M. Dordio, Anna Threlfall, Cláudia Gomes, Amanda Paul, Mirja Nolff, Nadja Sieber-Ruckstuhl, Ghita Benchekroun, et al.

    Background: The survival of dogs with pheochromocytoma (PCC) treated with adrenoreceptor antagonists has not been described or compared to surgically managed cases. Hypothesis/Objectives: The objective of this study is to evaluate the survival of medically and surgically managed dogs with PCC and investigate factors associated with survival. Animals: Two hundred fifty-five dogs with PCC, treated with alpha-adrenoreceptor antagonists (AA) without adrenalectomy (Group 1, n = 75), adrenalectomy +/– AA (Group 2, n = 128), or neither treatment (Group 3, n = 52). Methods: Retrospective, multicenter review of medical records. Median overall survival time (OST) for Groups 1 and 2 combined was calculated using Kaplan–Meier estimates, and then compared between Group 1 and Group 2 using Log-Rank testing. Cox proportional hazard analysis identified factors associated with survival in Groups 1 and 2 individually and combined. Results: Median OST for all cases was 854 (95% CI: 572–1136) days. Median OST was lower in Group 1 (247 days, 95% CI: 76–418 days) than in Group 2 (927 days, 95% CI: 587–1267 days; p < 0.001). In Group 2, 88/92 dogs (97.8%) that received presurgical AA treatment survived to discharge compared to 23/27 (85.2%) that did not receive AA pretreatment (p = 0.03). Lack of clinical signs at presentation was associated with increased survival in both groups combined (HR 0.5; 95% CI 0.3–0.9; p = 0.02) and in Group 2 alone (HR 0.3; 95% CI 0.1–0.7; p = 0.01). Conclusions and Clinical Importance: Dogs with PCC treated with adrenalectomy have longer survival compared to those managed with AA without adrenalectomy.


  • Open Access

    Clinical findings, treatment, and outcomes in cats with naturally occurring hypoadrenocorticism: 41 cases

    by Emma Roberts, Ian K. Ramsey, Ruth Gostelow, Anna Latysheva, Luca Battaglia, Paolo Silvestrini, Ghita Benchekroun, Karen Brenner, Bérénice Conversy, Riccardo Ferriani, et al.

    Background: Hypoadrenocorticism in cats is uncommonly reported. Most reports consist of cats with hyponatremia, hyperkalemia, or both. Hypothesis/Objectives: To describe clinical findings, treatment response, and outcome in cats diagnosed with hypoadrenocorticism, including cats with abnormal and normal serum sodium and potassium concentrations. Animals: Forty-one cats with hypoadrenocorticism; 36 with and 5 without abnormal serum sodium and potassium concentrations. Methods: Multicenter retrospective observational study. Data for the entire cohort were assessed using descriptive statistics and differences between cats with and without abnormal serum sodium and potassium concentrations were evaluated. Results: Median age was 5.7 years (range, 0.2-13.8). Twenty-three (56%) cats were male and 18 (44%) were female. Cats with hyponatremia, hyperkalemia, or both were less likely to have a history of vomiting (P = .01) but more likely to be hypothermic (P = .03), dehydrated (P = .04) or weak (P = .04) on examination, compared with nonhyponatremic and nonhyperkalemic cats. Frequency of hypercalcemia was 31.7%. Exocrine pancreatic insufficiency (EPI) was diagnosed in 4/7 cats tested; all 4 had concurrent cobalamin deficiency. Thirty-five (85.4%) cats survived to discharge. In 2 cats, hypoadrenocorticism occurred secondary to lymphoma. Median survival time (MST) for all-cause mortality was 2035 days (95% confidence interval [CI], 294-4380 days); MST for disease-specific mortality was not reached. Conclusions and Clinical Importance: Approximately one-third of cats with hypoadrenocorticism had hypercalcemia. In some cases, hyponatremia and hyperkalemia were not observed. Cats with nonneoplastic associated hypoadrenocorticism that survive initial hospitalization can have a favorable long-term prognosis. Testing for EPI may be warranted in cats with hypoadrenocorticism.


  • Open Access

    Resting cortisol concentrations in dogs presenting to a university teaching hospital with collapse

    by Ana Fernandez Gallego, Craig Robert Breheny, Adam G. Gow, Alisdair M. Boag

    Background: The relationship between collapse and a diagnosis of hypoadrenocorticism is not well understood in dogs. Hypothesis: To assess the prevalence of episodes of collapse in dogs screened for hypoadrenocorticism, and to assess the prevalence of confirmed hypoadrenocorticism in dogs presenting with reported collapse. Animals: Seventy-three client-owned dogs with resting cortisol concentrations were measured and presented to a University teaching hospital for collapse. Methods: Retrospective review of medical records of dogs at a single center. Results: The prevalence of episodes of collapse in dogs that had a resting cortisol measurement was 73/856 (8.5%; 95% confidence interval [95% CI], 6.7%-10.6%). Resting cortisol concentration was 55 nmol/L). The most common diagnosis was vasovagal syncope (10/73), followed by sick sinus syndrome and third-degree atrioventricular block (2/73). The final diagnosis was unknown in 24/73 dogs. Conclusions and Clinical Importance: Hypoadrenocorticism was the final diagnosis in 1 of 73 dogs presented to a teaching hospital either in a collapsed state or with a previous history of episodes of collapse. No dog presenting as cardiovascularly stable for intermittent collapse was found to have hypoadrenocorticism.

  • Open Access

    Hypoadrenocorticism in cats: a 40-year update

    by Magdalena J Glebocka, Alisdair Boag

    Practical relevance: Addison’s disease is a very rare condition in cats, with only approximately 40 cases documented in the past 40 years since it was first described in 1983. Clinical challenges: While canine hypoadrenocorticism is a well-recognised disorder with clear diagnostic and treatment guidelines, feline hypoadrenocorticism remains a challenge because of its rarity and waxing and waning clinical signs. Furthermore, empirical treatment with corticosteroids, resulting in clinical improvement, contributes to delays in achieving the diagnosis and initiating treatment. Feline hypoadrenocorticism is diagnosed with an adrenocorticotropic hormone (ACTH) stimulation test; a low resting cortisol concentration with an inadequate or absent response to synthetic ACTH is diagnostic. Various ACTH stimulation-testing protocols are reported in published cases, with the majority using three time-limited blood samples. This can be limiting clinically, depending on cats’ clinical presentation and behaviour at the veterinary practice and tolerance for procedures. Long-term treatment, similar to canine hypoadrenocorticism, consists of oral corticosteroids, with several formulations licensed in the UK, and mineralocorticoids (desoxycorticosterone pivalate), of which the only available formulation (Zycortal; Dechra) is licensed for dogs and its safety has not been assessed in cats. Global importance: Feline hypoadrenocorticism occurs worldwide. Although no breed, sex or age association has been reported, cats aged <6 years are overrepresented.


  • Open Access

    A retrospective study of hydrocortisone continuous rate infusion compared with administration of dexamethasone boluses in dogs with adrenal crisis

    by Lara Brunori, Olivia X. Walesby, Daniel H. Lewis, Alisdair M. Boag

    Background: Evidence indicating the optimal treatment protocol for dogs in adrenal crisis is lacking. Objectives: Compare outcomes of dogs presented in adrenal crisis treated with either hydrocortisone (HC) continuous rate infusion (CRI) or intermittent dexamethasone (DEX) administration. Animals: Thirty-nine client-owned dogs. Methods: Multi-institutional retrospective observational study (July 2016-May 2022) including dogs diagnosed with adrenal crisis and with available sequential blood work during hospitalization. Dogs were excluded if already on treatment with exogenous corticosteroids. Outcomes assessed included duration of hospitalization, survival, number of repeat measurements of electrolyte concentrations, and time to normalization of electrolyte and acid-base status. Results: No significant difference was found between the groups for hospitalization time (P = .41; HC median [range] 48 h [19-105 h]; DEX 57 h [17-167 h]) nor case fatality rate 2/28 in the DEX group and 0/11 in the HC group (P = 1), nor in number of measurements of electrolyte concentrations (P = .90; HC 4 [2-10]; DEX 4.5 [2-15]). No significant differences were found between the 2 treatment groups in time to normalization of serum Na (P = .30; HC 33 h [7-66 h]; DEX 16 h [1.5-48 h]), K (P = .92; HC 17 h [4-48 h]; DEX 16 h [1.25-60 h]) or Na/K ratio (P = .08; HC 17 h [8-48 h]; DEX 26 h [1.5-60 h]). Conclusions: This study detected no difference in outcomes for dogs in adrenal crisis treated with either DEX boluses or HC CRIs.


  • Open Access

    Juvenile primary acquired hypothyroidism in a dog with suspected renal dysplasia

    by Sophie Parton, Callum Atkins, Alisdair M. Boag, Glynn Woods

    A 1‐year 3‐month‐old, female, neutered crossbreed dog presented for investigation of polyuria, polydipsia and azotaemia. Subsequent biochemistry, endocrine testing and abdominal ultrasound identified hypercholesterolaemia, thyroglobulin autoantibody‐positive hypothyroidism, and IRIS stage II non‐hypertensive, non‐proteinuric suspected renal dysplasia, with a concurrent Escherichia coli urinary tract infection. The patient responded well clinically to levothyroxine treatment, with improvement in hypercholesterolaemia, azotaemia and demeanour at home. At follow‐up biochemistry assessment, hyperphosphataemia and hypercalcaemia (total and ionised) were documented, presumed to be driven by renal insufficiency and renal secondary hyperparathyroidism, although this aetiology was not definitively proven. Normalisation of these values was noted following renal diet implementation and addition of phosphate binders. This case highlights acquired primary hypothyroidism with evidence of thyroiditis in a juvenile dog with suspected congenital renal dysplasia.

  • Open Access

    Serum metabolomic profiles in dogs with chronic enteropathy

    by Hannah K. Walker, Alisdair M. Boag, Claudia Ottka, Hannes Lohi, Ian Handel, Adam G. Gow, Richard J. Mellanby

    Background: Metabolic profiles differ between healthy humans and those with inflammatory bowel disease. Few studies have examined metabolic profiles in dogs with chronic enteropathy (CE). Hypothesis: Serum metabolic profiles of dogs with CE are significantly different from those of healthy dogs. Animals: Fifty-five dogs with CE and 204 healthy controls. Methods: A cross-sectional study. The serum concentrations of 99 metabolites measured using a canine-specific proton nuclear magnetic resonance spectroscopy platform were studied. A 2-sample unpaired t-test was used to compare the 2 study samples. The threshold for significance was set at P < .05 with a Bonferroni correction for each metabolite group. Results: Nineteen metabolites and 18 indices of lipoprotein composition were significantly different between the CE and healthy dogs. Four metabolites were significantly higher in dogs with CE, including phenylalanine (mean and SD) (healthy: 0.0417 mmol/L; [SD] 0.0100; CE: 0.0480 mmol/L; SD: 0.0125; P value: <.001) and lactate (healthy: 1.8751 mmol/L; SD: 0.7808; CE: 2.4827 mmol/L; SD CE: 1.4166; P value: .003). Fifteen metabolites were significantly lower in dogs with CE, including total fatty acids, and glycine (healthy: 0.2273 mmol/L; SD: 0.0794; CE: 0.1828 mmol/L; SD CE: 0.0517; P value: <.001). Conclusions and Clinical Importance: The metabolic profile of dogs with CE is significantly different from that of healthy dogs, this opens novel research avenues to develop better diagnostic and prognostic approaches as well as therapeutic trials.


  • Open Access

    Evaluation of resting cortisol concentration testing in dogs with chronic gastrointestinal signs

    by Ana Fernandez Gallego, Adam G. Gow, Alisdair M. Boag

    Background: Resting cortisol concentrations are routinely measured in dogs with chronic gastrointestinal signs to rule out hypoadrenocorticism based on a concentration >2 μg/dL (>55 nmol/L). Hypothesis/Objectives: To assess the cross-sectional prevalence of hypoadrenocorticism in a group of dogs with chronic gastrointestinal signs presented to a referral internal medicine service. Animals: Two-hundred and eighty-two client-owned dogs with chronic gastrointestinal signs and with resting cortisol concentration testing performed. Methods: Retrospective review of medical records (final diagnosis, resting cortisol concentration, and adenocorticotropic hormone [ACTH] stimulation test results) of a referral population of dogs between May 2013 and September 2017. Results: Resting cortisol concentration was 55 nmol/L). Overall, the most common diagnosis was chronic primary inflammatory enteropathy (176/282, 62.4%), followed by extragastrointestinal neoplasia (17/282, 6%), protein-losing enteropathy, pancreatitis and megaesophagus (10/282, 3.5% each). Conclusions and Clinical Importance: Although dogs with hypoadrenocorticism can present with chronic gastrointestinal signs, it was the final diagnosis in only 1 of 282 dogs presenting to a referral internal medicine service for signs of chronic enteropathy. Repeated resting cortisol concentration may be considered as a test to try and exclude hypoadrenocorticism.


  • Open Access

    Xanthogranulomatous Pituitary Adenoma in a Dog with Typical Hyperadrenocorticism

    by Ana Fernández-Gallego, Jorge Del-Pozo, Alisdair Boag, Scott Maxwell, Jorge Pérez-Acino